Pulmonary antibody-mediated rejection has dismal outcomes and no established treatment platform
Evidence level: proposed bottleneck; synthesis of abstract-level sources; pending approval
The 2026 ISHLT statement reports a 2-year survival of only 20 percent for pulmonary AMR and calls better treatments a critical unmet need.
As of . Primary source: ISHLT scientific statement on pulmonary AMR (DOI).
Summary
The 2026 ISHLT scientific statement proposes a Graft, Antibody and Pathology (GAP) definition of pulmonary antibody-mediated rejection and states that outcomes remain dismal with a 2-year survival of only 20 percent, that better treatments are a critical unmet need, and that a more precise definition could provide a platform for testing therapies. A registered phase 1 trial of fostamatinib in recipients with donor-specific antibodies is listed on this site. The relationship between pulmonary AMR and CLAD onset was not read in these sources, so this record is broader than CLAD alone and has lower confidence than the others.
Details
- barrier type
- therapeutic evidence
Sources and links
Related
Links from this record
- evidence: International Society for Heart and Lung Transplantation Scientific Statement on pulmonary antibody-mediated rejection and proposed graft, antibody, and pathology (GAP) definition
- affects: Antibody-mediated rejection and donor-specific antibodies
- affects: HLA donor-specific antibody and non-HLA antibody testing
- tests: Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies
- affects: Humoral (antibody-mediated) alloimmunity
Known gaps in this record
- the GAP criteria (full text not read)
- link between AMR and CLAD onset in the sources opened
Information resource only. Not medical advice. Not a substitute for the care of the patient's transplant team.